ArticleCureus2025
Pretreatment Inflammatory Indices as Predictors of Survival in Endometrial Cancer: A Retrospective Cohort Study From Mexico.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a neutrophil percentage to albumin ratio-based nomogram for predicting survival in patients with locally advanced gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNutritional and inflammatory prognostic indices derived from biochemical and hematological parameters are emerging as potential prognostic biomarkers in various malignancies, including endometrial cancer.
objectiveThe objective of this study is to evaluate whether pre-treatment biomarkers of systemic inflammation are associated with survival outcomes in patients with endometrial cancer.
methodsThis retrospective cohort study included women treated for endometrial cancer at a single institution. Pre-treatment Onodera's Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Lymphocyte-to-Monocyte Ratio (LMR), and Systemic Immune-Inflammation Index (SIII) were calculated, with cutoff values determined using receiver operating characteristic (ROC) curves and quartiles. Associations with overall survival (OS) were analyzed using Kaplan-Meier estimation and multivariable Cox proportional regression, adjusting for the International Federation of Gynecology and Obstetrics (FIGO) stage, histology, grade, and adjuvant therapy. Odds ratios (ORs) were used due to the retrospective design.
resultsWe included 887 patients who underwent initial staging surgery between 1997 and 2019. The median age was 55.27 years, with a median follow-up of 59.63 months. High NLR (>2.8, OR 1.90, 95% confidence interval (CI): 1.26-2.87, p=0.002) and PLR (>103.2) and low LMR (<4.8, OR 2.09, 95% CI 1.39-3.15, p<0.001, area under the curve (AUC) 0.589, 95% CI 0.54-0.64) and PNI (<40.0) were associated with reduced five-year OS. The LMR demonstrated the highest, though modest, precision in AUC analysis and was significantly associated with OS and mortality risk. These indices may guide adjuvant therapy decisions in resource-limited settings.
conclusionPre-treatment inflammatory indices, particularly LMR, are promising prognostic biomarkers for OS in endometrial cancer, offering accessible tools for risk stratification in low-middle-income settings. These indices should not replace established clinical prognosticators but may provide additive value. Prospective, multicenter studies are needed to confirm these findings and integrate them into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.